blood clots

(±) Clopidogrel hydrogen sulfate (Iscover) , an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots.

Vicagrel is an effective, orally active antiplatelet compound that enhances the inhibitory effect of aspirin on platelet aggregation and thrombosis in rodents by irreversibly inhibiting P2Y12 receptors and reducing metabolic inactivation. Viagrel can be used to treat blood clots in coronary artery disease, peripheral vascular disease and cerebrovascular disease.

Omega-3 Arachidonic Acid ethyl ester, a rare polyunsaturated fatty acid with limited presence in dietary sources, is crucial for infant growth and development and offers protection against heart disease, blood clots, high blood pressure, and inflammatory and autoimmune disorders. In human platelet membranes, it impedes arachidonyl-CoA synthetase, exhibiting a Ki of 14 μM, and shows similar inhibitory effects on arachidonoyl-CoA synthetase in calf brain extract with an IC50 of roughly 5 μM. The ethyl arachidonate derivative offers enhanced lipophilicity compared to its free acid counterpart.

Nattokinase is a powerful fibrinolytic enzyme that effectively hydrolyzes fibrin and plasmin substrate, leading to the breakdown of blood clots. Its efficacy renders it valuable for cardiovascular disease studies.

Fibrin, the primary constituent of blood clots, is an insoluble protein essential for coagulation. Isolated from bovine blood, this protein is notably synthesized in response to bleeding.

Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI)

Anagrelide hydrochloride monohydrate is a imidazoquinazoline agent. Anagrelide hydrochloride monohydrate decreases the level of platelets in blood, prevents blood clots formation. Anagrelide hydrochloride monohydrate can be used for research of essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV) [1] .

Dazoxiben is an antithrombotic agent used to reduce the formation of blood clots.

rac-Clopidogrel-d4 Hydrogen Sulfate is a deuterated compound of rac-Clopidogrel Hydrogen Sulfate. rac-Clopidogrel Hydrogen Sulfate has a CAS number of 135046-48-9. Clopidogrel, an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex.

Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y12 receptor (IC50 = 100 nM). Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite via CYP2C19 in the liver enables its anti-aggregating activity. Marketed under the name Plavix , clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascular ischemic events for patients without deficiencies in CYP2C19-related metabolism.

Clopidogrel (SR-25990C), a P2Y12 receptor antagonist, decreases platelet aggregation.

Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) , a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation.